(Q80671893)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17652059%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

title

Carcinoma of unknown primary site: development in a single institution of a prognostic model based on clinical and serum variables (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17652059%20AND%20SRC:MED&resulttype=core&format=json

carcinoma of unknown primary

2 January 2020

main subject

1 reference

J Ponce Lorenzo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17652059%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

A Segura Huerta

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17652059%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

R Díaz Beveridge

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17652059%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

A Giménez Ortiz

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17652059%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

F Aparisi Aparisi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17652059%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

T Fleitas Kanonnikoff

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17652059%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

P Richart Aznar

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17652059%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

H de la Cueva Sapiña

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17652059%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

J Montalar Salcedo

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17652059%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

publication date

1 July 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17652059%20AND%20SRC:MED&resulttype=core&format=json

Clinical and Translational Oncology

2 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17652059%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17652059%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17652059%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

page(s)

452-458

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17652059%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s12094-007-0084-6

2 January 2020

exact match

0 references

cites work

Diagnostic and therapeutic management of cancer of an unknown primary

1 reference

12 December 2020

Gemcitabine and oxaliplatin for patients with advanced or metastatic pancreatic cancer: a North Central Cancer Treatment Group (NCCTG) phase I study

1 reference

12 December 2020

Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site

1 reference

12 December 2020

Metastatic adenocarcinomas of unknown primary site. Prognostic variables and treatment results

1 reference

12 December 2020

Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience

1 reference

12 December 2020

Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01).

1 reference

12 December 2020

Cancer of unknown primary site

1 reference

12 December 2020

Chemotherapy in carcinomas of unknown primary site: a high-dose intensity policy.

1 reference

12 December 2020

Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma

1 reference

12 December 2020

Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study

1 reference

12 December 2020

Alternative bimonthly cycles of doxorubicin, cyclophosphamide, and etoposide, cisplatin with hematopoietic growth factor support in patients with carcinoma of unknown primary site.

1 reference

12 December 2020

Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin

1 reference

12 December 2020

Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer.

1 reference

12 December 2020

Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site

1 reference

12 December 2020

Evaluation of survival data and two new rank order statistics arising in its consideration

1 reference

12 December 2020

Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site : results of an Italian multicenter, randomized, phase II study

1 reference

12 December 2020

Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients

1 reference

12 December 2020

A phase II study of carboplatin and paclitaxel in adenocarcinoma of unknown primary

1 reference

12 December 2020

Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma

1 reference

12 December 2020

Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site

1 reference

12 December 2020

Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study

1 reference

12 December 2020

Empirical chemotherapy for adenocarcinoma of unknown primary tumor site

1 reference

12 December 2020

Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer

1 reference

12 December 2020

Treatment of patients with cancer of an unknown primary site

1 reference

12 December 2020

Unknown primary tumours

1 reference

12 December 2020

DNA microarrays in clinical oncology

1 reference

12 December 2020

Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study

1 reference

12 December 2020